Needham Reiterates Buy on Freeline Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Patrick Trucchio has reiterated a 'Buy' rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a price target of $15.

August 04, 2023 | 9:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Freeline Therapeutics' stock rating has been reiterated as 'Buy' by Needham analyst Patrick Trucchio, with a maintained price target of $15.
The reiteration of a 'Buy' rating by a reputable analyst like Patrick Trucchio is a positive signal for investors. The maintained price target of $15 indicates that the analyst believes the stock has potential for growth, which could lead to an increase in demand and subsequently, a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100